Treatment with the IL-23 inhibitor significantly improved skin clearance in the pediatric study of children aged 6-17 with ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Biotechnology firm Biocon on Wednesday said its unit has inked a settlement and license agreement with Amgen Inc., paving the ...

Blood sample collection in lizards is an important technique. This column describes techniques for sample collection from the ventral coccygeal vein and the ventral abdominal vein. The ventral ...

Biocon inks deal with Amgen to market Bosaya & Aukelso biosimilars (Prolia & Xgeva copies) in the US from Oct 2025.

The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...

By ensuring timely wound care, vaccination, immunoglobulin administration, and responsible interaction with animals, rabies ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...

Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) ...

Bengaluru: Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced ...

Tralokinumab self-administered by patients with atopic dermatitis via a pre-filled pen is a safe and effective treatment option.